

CIRM Funded Clinical Trials

A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease

Disease Area:	X-linked Chronic Granulomatous Disease
Investigator:	Donald Kohn
Institution:	University of California, Los Angeles
CIRM Grant:	CLIN2-08231
Award Value:	\$7,083,364
Trial Sponsor:	University of California, Los Angeles
Trial Stage:	Phase 1/2
Trial Status:	Active, not recruiting
Targeted Enrollment:	10
ClinicalTrials.gov ID:	NCT02234934



Donald Kohn

Details:

X-linked Chronic Granulomatous Disease (X-CGD) is a rare immune disorder that prevents white blood cells from killing foreign invaders. This results in severe, recurrent infections that can impact quality and length of a patient's life. X-CGD is usually diagnosed before age 5, but without treatment, children die before age 10. A team at UCLA is using the patient's own genetically modified blood stem cells to create a new blood supply and a healthy immune system, with the aim of curing patients with this disease.

Design:

X-linked Chronic Granulomatous Disease.

Goal:

Primary: Safety and Efficacy. Secondary: Restoration of immune function

Updates:

Enrolling. Early evidence of clinical efficacy.

Contact Trial Sponsor